Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting - Summary - MDSpire
From the Journals

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

  • April 30, 2026

Share

Large panel liquid biopsy assays, encompassing over 300 genes, are evolving in the clinical landscape due to technical advancements and decreasing costs per sample. Laboratories are beginning to incorporate these assays for comprehensive genomic profiling (CGP) as they offer shorter turnaround times compared to traditional FFPE tissue methodologies. Dr. Gang Zheng from the Mayo Clinic discusses their experiences, including performance metrics of their TSO 500 ctDNA v2 assay, which utilizes blood and CSF to ensure accurate variant reporting and facilitate research applications.

Original Source(s)

Related Content